V

Varian

Tech-enabled radiation oncology hardware and software

Financial Analyst - Global R&D Controller

Full-Time
$117.8k - $161.9k
Mid, Senior
Bachelor's, Master's, MBA
Canada
HybridHybrid work arrangement.
Finance & BankingCorporate Finance & FP&A

About the job

Requirements
  • A bachelor's degree in Accounting, Finance, or Business is required.
  • Three to five years of progressive analytical and controlling experience, with demonstrated career progression in a similar environment.
  • Ability to distill business processes and results into actionable information for senior leadership and deliver presentations.
  • Ability to analyze, organize, and maintain quality, while balancing activities to meet tasks and due dates.
  • Communication and networking skills, result and quality orientation, a proactive attitude, intercultural sensitivity, and ability to establish virtual networks across cultures and locations.
  • Ability to manage horizontal teams and lead cross-functional efforts; experience coordinating business operations, finance, accounting, audit, and external personnel across levels.
  • Knowledge and experience in project management, strong attention to detail, and strong analytical ability.
  • Business acumen and understanding of complex organizational and reporting structures, processes, budgeting, and forecasting.
  • Strong systems skills in SAP, expert Excel and PowerPoint capabilities, and SAP BW (Data Warehouse reporting) experience.
  • Familiarity with healthcare research and development methodology and requirements.
  • Understanding and ability to apply intangible capitalization of development projects and its impact on the profit and loss statement, balance sheet, and cash flow statement.
  • Ability to optimize and standardize process workflows and a track record of driving business improvements based on prior experience.
  • Ability to work with controlled technology in accordance with U.S. export control law.
Responsibilities
  • Guide analysis of financial results to determine the accuracy and completeness of information.
  • Develop financial reports and review financial plans and budgets with management, including complex analyses of rate of return, depreciation, working capital, investments, budgeting, and financial and expense performance comparisons.
  • Guide and maintain conformance with International Financial Reporting Standards requirements and coordinate with auditors.
  • Drive and optimize financial performance for research and development and capital investment projects; recommend actions to management to deliver on targets using data-driven decision-making, align the organization, and collaborate with stakeholders monthly to implement targeted performance improvements.
  • Analyze monthly forecast and actual variances, gather and evaluate key project activities and statuses affecting forecasts, and report to the senior management team.
  • Conduct financial project plans for ongoing and new research and development projects.
  • Conduct quarterly ASTAR reporting and compliance certification.
  • Conduct quarterly research and development tax surveys and compliance.
  • Maintain functional independence and provide the Point of Care Business Line with proactive communication and analysis.
  • Coordinate the business unit's monthly, quarterly, and annual financial cadence for Point of Care research and development, including forecasting, actual reporting and analysis, budgeting, and strategic planning.
  • Provide key presentations on financial status at management team meetings.
  • Travel approximately 10% of the time.
Desired Qualifications
  • A master's degree, MBA, CPA, or equivalent.
  • Experience in an international business setting and experience working and communicating across multiple cultures.
  • Strong experience with data analytics tools.
  • Experience in healthcare and understanding of healthcare industry dynamics, especially healthcare diagnostics.

About the company

Varian, part of Siemens Healthineers, focuses on oncology by providing integrated radiation oncology solutions that combine software, hardware, patient data, and care teams. Its offerings include treatment-planning software, radiation therapy machines, and data-management systems that work together to enable precise cancer treatments. The company differentiates itself through an integrated platform approach and services like Oncology-as-a-Service (OaaS), which lets healthcare providers adopt advanced radiation oncology with ongoing service support rather than large upfront investments. Varian serves healthcare providers such as hospitals and cancer centers, helping them deliver coordinated care and improve patient outcomes. Its goal is to reduce the fear of cancer by using data and technology to support clinicians in delivering effective treatments.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

1948

Get referred to Varian

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ARPA-H awarded Varian up to $60 million in April 2026 for FLASH-RT.
  • FDA cleared TrueBeam for osteoarthritis in March 2026, opening a non-cancer market.
  • Telix collaboration and 2026 AI approvals expand Varian's clinical and software pipeline.

What critics are saying

  • RaySearch enabled online adaptive TrueBeam workflows in Belgium in May 2026, eroding software differentiation.
  • Elekta still attacks Varian's lead in adaptive radiotherapy and premium MR-guided care.
  • If FLASH and non-oncology bets fail by 2028, Varian becomes a commoditized linear-accelerator vendor.

What makes Varian unique

  • Siemens Healthineers gives Varian imaging, radiotherapy, and capital-sales integration globally.
  • Varian's 2026 CE-marked Eclipse AI contouring deepens workflow lock-in across planning.
  • TrueBeam, Halcyon, and Ethos create an installed-base moat hospitals rarely replace.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Holidays

Health Insurance

Dental Insurance

Vision Insurance

Wellness Program

401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Varex Imaging Corporation
Sep 14th, 2026
About Us | Varex Imaging Corporation

We strive to help customers become world-class system suppliers by strengthening their competitiveness and enabling them to bring products to market faster

MEDQOR
Apr 30th, 2026
Siemens Healthineers secures $83M to develop photon Flash radiotherapy for cancer treatment

Siemens Healthineers has received up to $60 million from the US Advanced Research Projects Agency for Health to develop photon Flash radiotherapy, with the company contributing an additional $23 million, totalling $83 million over five years. Flash photon therapy delivers radiotherapy more than 100 times faster than current technologies, aiming to reduce side effects and improve healthy tissue sparing. Unlike proton and electron beam platforms, which face scalability challenges, photon beams are the standard of care for over 50% of cancer patients. The project will build on existing C-arm linear accelerators to enable broader clinical access. Siemens Healthineers aims to transition ultra-high dose rate radiotherapy from experimental treatment into global standard of care within the five-year timeframe.

Business Wire
Mar 19th, 2026
Varian TrueBeam gets FDA clearance for low-dose radiotherapy to treat osteoarthritis

Siemens Healthineers has received FDA 510(k) clearance for its Varian TrueBeam radiotherapy systems to treat medically refractory osteoarthritis in adults using low-dose radiation therapy. This marks the first expansion of Varian's radiotherapy platform beyond cancer care into chronic musculoskeletal conditions. Osteoarthritis affects over 33 million adults in the US and approximately 600 million globally. The clearance covers TrueBeam, TrueBeam STx, VitalBeam and Edge systems, offering patients with persistent pain a non-invasive outpatient treatment option that targets inflammation, reduces pain and improves joint function. The approval builds on Varian's previous regulatory clearances for non-oncological indications, including radiosurgery treatment for medically refractory essential tremor. The TrueBeam platform combines high-resolution imaging with precise dose control whilst maintaining streamlined clinical workflows.

AuntMinnieEurope.com
Dec 10th, 2025
Telix and Varian enter research collaboration

Telix and Varian enter research collaboration. Telix Pharmaceuticals and Siemens Healthineers' company Varian have agreed to develop novel clinical applications that combine Telix's theranostics products and Varian's external beam radiation therapy (EBRT) technology. The first area of focus will be in identifying opportunities to use Telix's prostate cancer PET imaging agents in selecting patients for EBRT, developing personalized treatment plans (particularly in the context of Varian's Ethos adaptive radiotherapy system), and monitoring responses to treatment, Telix said. The agreement supports both company-sponsored and investigator-led clinical studies. Varian is a key player in EBRT and working with the company will allow Telix to explore how theranostics can be used more effectively by radiation oncologists to enhance patient selection and deliver targeted treatment, Telix noted. I agree to receive marketing related digital communications about products, services, events and offers that may be relevant to my given user preferences and behavior. I agree to share my information with the sponsor. I have read and agree to the privacy policy & terms of service and wish to opt-in.

AuntMinnie.com
Mar 28th, 2025
Varian, Embolx sign image-guided microcatheter agreement

Siemens Healthineers company Varian has entered into a sales and marketing agreement with Embolx for its Sniper Balloon Occlusion Microcatheter.